Mursla Bio
Mursla Bio is a biotech company on a mission to significantly improve cancer outcomes for at-risk patients through the power of Dynamic Biopsy. The Company’s proprietary biopsy platform non-invasively analyzes dynamic biological processes within a specific organ or tissue to assess its health condition. This approach combines the accuracy and disease sub-typing capabilities of tissue biopsies with the ease of liquid biopsy sample collection. Dynamic Biopsy is made possible by advanced extracellular vesicle (EV) science and an innovative approach called extracellular omics, supported by Mursla Bio’s pioneering technologies. These technologies include organ-specific EV isolation from biofluids for precise targeting, an AI-enabled multi-omics workflow for disease biomarker identification, and a scalable assay platform using optimal biomarkers for clinical use. Mursla Bio is initially focused on transforming the surveillance of liver cancer in high-risk populations - the fastest growing cause of cancer related deaths. Mursla Bio is developing its first Dynamic Biopsy-based blood test, EvoLiver™.Content by Mursla Bio
| 2 min read
Mursla Bio Introduces AI Precision Medicine Platform Built on Organ-Specific EV Isolation from Blood
Enables differentiated AI-powered biomarker discovery and IVD translation for patient stratification, therapeutic monitoring, surrogate markers and other diagnostic development programs
Page 1 of 1 - 1 Total Items
